RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182

Benzinga Newsdesk www.benzinga.com Positive 92.0%

Neg 0% Neu 0% Pos 92%

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $165 to $182.